Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study
BioDrugs · 2026-05 · 40 (3) · 493-495
DOI: 10.1007/s40259-026-00772-2 ↗Kurz gefasst
Leserbrief in der Zeitschrift BioDrugs, online erschienen am 11.03.2026. Verfasst von Teppei Hagino und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba, 270-1694, Japan. teppei-hagino@nms.ac.jp. Die Arbeit nennt 5 Literaturangaben. Gefördert von: Maruho Takagi Dermatology Foundation, Torii Pharmaceutical.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba, 270-1694, Japan. teppei-hagino@nms.ac.jp.
- Department of Dermatology, Nippon Medical School, Tokyo, Japan.
- Department of Dermatology, Fujimoto Dermatology Clinic, Funabashi, Japan.
- Department of Dermatology, Nippon Medical School Chiba Hokusoh Hospital, Kamagari 1715, Inzai, Chiba, 270-1694, Japan.
Förderung
- Maruho Takagi Dermatology Foundation
- Torii Pharmaceutical
Zitieren
APA
Hagino, T., Saeki, H., Fujimoto, E., & Kanda, N. (2026). Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study. BioDrugs, 40(3), 493-495. https://doi.org/10.1007/s40259-026-00772-2
Vancouver
Hagino T, Saeki H, Fujimoto E, Kanda N. Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study. BioDrugs. 2026;40(3):493-495. doi:10.1007/s40259-026-00772-2
BibTeX
@article{Hagino2026,
author = {Hagino, Teppei and Saeki, Hidehisa and Fujimoto, Eita and Kanda, Naoko},
title = {Effectiveness of Lebrikizumab Treatment for Patients with Atopic Dermatitis Switched from Dupilumab or Tralokinumab: A 48-Week Real-World Retrospective Study},
journal = {BioDrugs},
year = {2026},
volume = {40},
number = {3},
pages = {493--495},
doi = {10.1007/s40259-026-00772-2}
}
EUVIMED